

Special Issue

Hybrid Nanosystems for Anticancer Therapy

Message from the Guest Editor

Hybrid nanostructures for cancer therapy are innovative platforms that integrate the advantages of nanomaterials and therapeutic agents to enhance cancer treatment. These nanostructures combine the unique properties of various materials, such as metals, polymers, and biomolecules, to achieve multifunctionality in diagnosis and therapy. On the one hand, hybrid nanostructures can improve the delivery and targeting of anticancer drugs, increasing their efficacy while reducing side effects. On the other hand, they can also facilitate synergistic therapies, such as combining photothermal therapy with chemotherapy, to induce more effective cancer cell destruction.

Moreover, the nanostructures' ability to incorporate imaging agents enables simultaneous diagnosis and treatment, known as theranostics. This Special Issue aims to collect recent research in the design and preparation of hybrid nanostructures and focuses on the use of them in biomedical fields, especially for anti-cancer treatment. We look forward to receiving your contributions.

Guest Editor

Dr. Deblin Jana

School of Engineering, Brown University, Providence, RI 02912, USA

Deadline for manuscript submissions

closed (20 March 2025)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/215189

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).